Reading time: 4 minutes Kate Secombe You may have read previously on OncoBites about immunotherapies, and the great promise they hold in treating a wide range of cancers. Commonly used immunotherapies include checkpoint inhibitors such as PD-1 or CTLA-4 inhibitors. Here I will be looking at an emerging subset of immunotherapies known as immune agonist... Continue Reading →
Reading time: 2 minutes Rachel Cherney Nature is magnificent, simply put. It is indispensable, diverse, and more complex than we currently understand. Its diversity ranges from from the Mantis Shrimp, which can see millions of colors as compared to humans, to the Axolotl, which has the remarkable ability to regenerative any of the limbs. However,... Continue Reading →
Reading time: 4 minutes Chamath Chandrasekera Proteins are the molecular machines that perform nearly every bodily function including contracting muscles, digesting food, and healing wounds. They also provide structural support by reinforcing the shape of cells and tissues. So how do proteins go from a string of amino acids to a 3D structure with a... Continue Reading →
Reading time: 5 minutes Chris Wang Chemotherapy is a mainstay of cancer treatment, yet many times it is temporarily withheld or stopped due to significant toxicity. This is because chemotherapy drugs cannot differentiate between killing cancer cells and killing fast growing healthy cells, such as cells in your bone marrow. These cells divide quickly because... Continue Reading →
Reading time: 4 minutes Daniel Zhong Before we believe headlines proclaiming “Cancer is cured”, it is crucial to understand that developing a therapy that universally cures all cancers is highly unrealistic as our knowledge surrounding mechanisms of cancer progression advances. While we do have non-curative treatments for some types of cancer such as chemotherapy and... Continue Reading →
Reading time: 4 minutes Brittany Avin McKelvey We are in a hayday for cancer therapies, as research has surpassed traditional chemotherapeutics. New drugs, new treatment regimens, and even new drug classes are approved each day, broadening the horizons of oncology. The newest types of drugs to recently gain FDA approval are tissue agnostic drugs. (See... Continue Reading →
Reading time: 5 minutes Aishwarya Subramanian The life cycle of cells is a key piece of our understanding of cancer; as cells grow, they divide and produce two new “daughter” cells. For the cells to divide, grow and survive, it requires energy which they gain by metabolising glucose. However, every healthy cell that divides has... Continue Reading →
Reading time: 5 minutes Bekah Schulz The Food and Drug Administration (FDA) is often criticized by patient advocacy groups for taking too much time to approve life-saving drugs. However, the FDA is a difficult situation; if they approve a drug too quickly and it turns out to be unsafe/ineffective, then people are upset. If they... Continue Reading →
Reading time: 4 minutes Kedar Puvar Designing new anticancer compounds is often a deliberate process, where the mechanism of action involves the blocking of a certain target, like a receptor or other cellular protein. Researchers would then optimize potential leads until a potent and effective drug is ready for clinical trials. This pipeline is considered... Continue Reading →
Reading time: 5 minutes Jessica Desamero From the start, our mission here at OncoBites has been to share the complicated nature of cancer with our readers and to shed light on breakthroughs in understanding and treating the disease. One of our biggest messages has been that “cancer” is really a family of different but related... Continue Reading →
Reading time: 3 minutes Kedar Puvar At first glance, mushrooms, being immobile and nutritious, seem to be rather unassuming. Why, then, would you want to turn to mushrooms of all things as a source of new medicines? It turns out that they make up for their evolutionary weaknesses with a powerful toolbox of molecular defenses... Continue Reading →
Reading time: 3 minutes Kedar Puvar Diseases are typically caused by defective or malicious proteins. Traditionally, treatments for these diseases use a strategy of inhibition - use a small molecule that can block the offending protein from carrying out its function and thereby, bring things back to normal. But what if we went one step... Continue Reading →
Reading time: 5 minutes Kaye Alcedo Even before President Nixon’s declaration of the “war on cancer” in 1971, the journey towards a cure was nothing but a rollercoaster ride. Many promising cancer drugs are tested in human clinical trials but ultimately fail primarily because they demonstrate inadequate efficacy or safety, costing billions of dollars, increasing... Continue Reading →
OncoBites 